Form 4 · Filed Jul 21, 2026, 09:24 PM UTC
ELVN/Enliven Therapeutics, Inc.
Hohl Benjamin — CHIEF FINANCIAL OFFICER
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
7 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | M | other | 1,072 | $2 | $2,659 | 52,072 |
| Jul 17, 2026 | S | sell | 324 | $50 | $16,191 | 51,748 |
| Jul 17, 2026 | S | sell | 369 | $51 | $18,997 | 51,379 |
| Jul 17, 2026 | S | sell | 2,564 | $52 | $134,143 | 48,815 |
| Jul 17, 2026 | S | sell | 2,638 | $53 | $140,823 | 46,177 |
| Jul 17, 2026 | S | sell | 123 | $54 | $6,626 | 46,054 |
| Jul 17, 2026 | M | other | 1,072 | — | — | 84,966 |
Source: SEC EDGAR raw filing ↗ · Accession 0001882764-26-000006